newsfilter
← Latest News
Business Wire·

Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results

- Biologics License Application (BLA) submission for veligrotug on track for second half 2025 with potential for U.S. launch in 2026; preparatory commercial activities underway - - REVEAL-1 and REVEAL-2, phase 3